NO BLEeding excess with thromboserin antiplatelet therapy during CABG

• Research type

  Research Study

• Full title

  Double blind placebo controlled study of the effect of the non-antihaemostatic drug thromboserin on platelet aggregates following coronary artery bypass grafting

• Contact name

  John Pepper

• Sponsor organisation

  Imperial College

• Eudract number

  2008-006428-70

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  Currently patients with coronary artery disease require drugs to reduce clots in arteries; these drugs cause bleeding. Bleeding is a great disadvantage in patients requiring surgical operations for this disease. The proposed study in such patients will evaluate a new drug which reduces clots in arteries, but does not cause bleeding and is safe. This will be done by analysis of blood taken from the patients before, during and after the coronary artery bypass operation (CABG).

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  08/H0806/91

• Date of REC Opinion

  15 Dec 2008

• REC opinion

  Further Information Favourable Opinion